-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Xalnesiran
| Category | Hepatitis B Virus (HBV) |
| CAS | 2538784-48-2 |
| Description | Xalnesiran, a revolutionary RNA-targeted pharmaceutical compound, has emerged as a cutting-edge treatment option for a spectrum of liver ailments such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Through precise mechanisms of action that involve suppression of critical disease-related genes, it showcases unparalleled efficacy in halting disease progression. |
Product Information
| Molecular Weight | 284.26 |
| Molecular Formula | C16H12O5 |
| Canonical SMILES | COC1=CC(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O)O |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
